ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 96.476 %w/w - barium sulfate without suspending agents - barium sulfate without suspending agents - for rectal administration (enema) as a radio-opaque agent for x-ray visualisation of the lower gastro-intestinal tract. it is designed for both single contrast barium enema and air-double contrast enema usage.

ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 96 %w/w - barium sulfate with suspending agents - barium sulfate with suspending agents - single - contrast radiography of the oesophagus stomach duodenum and small bowel. for use only in x-ray departments.

ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate - אבקה להכנת תרחיף - barium sulfate 98.3845 %w/w - barium sulfate without suspending agents - barium sulfate without suspending agents - for double contrast radiography of the oesophagus, stomach and duodenum.

ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate - תרחיף - barium sulfate 4.9224 %w/v - barium sulfate containing x-ray contrast media - for use in x-ray departments.opacification of the gastro intestinal tract prior to computerized axial tomography.

ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate - תרחיף - barium sulfate 105 %w/v - barium sulfate containing x-ray contrast media - for use only in x-ray departments. single or double contrast radiographic visualization of the lower gastro intestinal tract.

ישראל - עברית - Ministry of Health

promedico ltd - barium sulfate 80.9977 %w/w - suspension - barium sulfate with suspending agents - radiolography of the gastro-intestinal tract. for use in x-ray departments.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 3 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.